The period right after release from incarceration is one of the highest-risk times for overdose, particularly for individuals who choose not to continue medical treatment for opioid use disorder. Wexford Health takes this risk seriously and works closely with each patient to ensure they understand what can happen if medication-assisted treatment (MAT/MOUD) is refused or abruptly discontinued upon release.

For patients nearing release who are on MAT, we offer options designed to protect their health and reduce the chance of relapse or overdose:

• Long-acting buprenorphine injection (Sublocade or Brixadi): Where funding allows, patients are offered and encouraged to transition to this extended-release treatment shortly before release, providing sustained protection without the need for daily medication.
• Tapering buprenorphine doses: For patients who choose to withdraw from MAT, we provide a supervised tapering process rather than an abrupt stop. This is not recommended around the time of release.
• Vivitrol injection: For patients who are fully withdrawn and interested in this option, a Vivitrol injection may be offered as an additional tool to support long-term recovery.

Just as important as the treatment itself is what comes after. Our care teams coordinate with community-based substance use disorder treatment providers in the patient's county and state, helping ensure continuity of care and a stronger support system once they return home.

Our goal is simple: every patient leaves incarceration with a clear understanding of their risks, options, and a plan for continued care — because recovery doesn't end at release.